Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1992 May;88(2):189–202. doi: 10.1111/j.1365-2249.1992.tb03061.x

B cell responses to HIV and the development of human monoclonal antibodies.

J E Boyd 1, K James 1
PMCID: PMC1554303  PMID: 1572084

Abstract

In this review B cell responses in HIV-infected individuals are summarized together with the techniques used to date to produce human monoclonals to HIV and the properties of these antibodies. Profound disturbances in B cell responses are apparent both in vivo and in vitro. While there is evidence in vivo of marked polyclonal B cell activation, primary and secondary antibody responses are impaired. Similarly these cells exhibit spontaneous immunoglobulin secretion upon in vitro culture but do not readily respond to B cell mitogens and recall antigens including HIV. Furthermore, certain of these defects can be reproduced in normal B cells in vitro by incubation with HIV or HIV coded peptides. Individuals infected with HIV develop antibodies to HIV structural proteins (e.g. p17, p24, gp41 and gp120) and regulatory proteins (e.g. vif, nef, RT). Autoantibodies against a number of immunologically important molecules are also frequently observed. The anti-HIV antibodies are predominantly of the IgG1 isotype and exhibit a variety of effects on the virus in vitro. To date, using conventional immortalization strategies, an appreciable number of human monoclonals to HIV have been developed. These have been specific for gp41, gp120 and gag with antibodies of the former specificity predominating. The majority of these antibodies have been of the IgG1 isotype. Only a small number of the antibodies neutralize virus in vitro and most of these react with gp120. The neutralizing antibodies recognize conformational and carbohydrate epitopes or epitopes in amino acid positions 306-322. The predominant epitopes recognized by the anti-gp41 antibodies were in amino acid positions 579-620 and 644-662. A high percentage (congruent to 25%) of these antibodies enhance viral growth in vitro. The problems relating to the production of human monoclonals to HIV are discussed together with strategies that could be used in the future.

Full text

PDF
201

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allain J. P., Laurian Y., Einstein M. H., Braun B. P., Delaney S. R., Stephens J. E., Daluga C. K., Dahlen S. J., Knigge K. M. Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance. Blood. 1991 Mar 1;77(5):1118–1123. [PubMed] [Google Scholar]
  2. Amadori A., Ciminale V., Calabro M. L., Tessarollo L., Francavilla E., Chieco-Bianchi L. Human monoclonal antibody against a gag-coded protein of human immunodeficiency virus produced by a stable EBV-transformed cell clone. AIDS Res Hum Retroviruses. 1989 Feb;5(1):73–78. doi: 10.1089/aid.1989.5.73. [DOI] [PubMed] [Google Scholar]
  3. Amadori A., De Rossi A., Faulkner-Valle G. P., Chieco-Bianchi L. Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. Clin Immunol Immunopathol. 1988 Mar;46(3):342–351. doi: 10.1016/0090-1229(88)90053-0. [DOI] [PubMed] [Google Scholar]
  4. Amadori A., Zamarchi R., Ciminale V., Del Mistro A., Siervo S., Alberti A., Colombatti M., Chieco-Bianchi L. HIV-1-specific B cell activation. A major constituent of spontaneous B cell activation during HIV-1 infection. J Immunol. 1989 Oct 1;143(7):2146–2152. [PubMed] [Google Scholar]
  5. Amadori A., Zamarchi R., Veronese M. L., Panozzo M., Barelli A., Borri A., Sironi M., Colotta F., Mantovani A., Chieco-Bianchi L. B cell activation during HIV-1 infection. II. Cell-to-cell interactions and cytokine requirement. J Immunol. 1991 Jan 1;146(1):57–62. [PubMed] [Google Scholar]
  6. Amadori A., Zamarchi R., Veronese M. L., Panozzo M., Mazza M. R., Barelli A., Borri A., Chieco-Bianchi L. B-cell activation during HIV-1 infection. III. Down-regulating effect of mitogens. AIDS. 1991 Jul;5(7):821–828. doi: 10.1097/00002030-199107000-00005. [DOI] [PubMed] [Google Scholar]
  7. Ammann A. J., Schiffman G., Abrams D., Volberding P., Ziegler J., Conant M. B-cell immunodeficiency in acquired immune deficiency syndrome. JAMA. 1984 Mar 16;251(11):1447–1449. [PubMed] [Google Scholar]
  8. Banapour B., Rosenthal K., Rabin L., Sharma V., Young L., Fernandez J., Engleman E., McGrath M., Reyes G., Lifson J. Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus. J Immunol. 1987 Dec 15;139(12):4027–4033. [PubMed] [Google Scholar]
  9. Barin F., McLane M. F., Allan J. S., Lee T. H., Groopman J. E., Essex M. Virus envelope protein of HTLV-III represents major target antigen for antibodies in AIDS patients. Science. 1985 May 31;228(4703):1094–1096. doi: 10.1126/science.2986291. [DOI] [PubMed] [Google Scholar]
  10. Berkman S. A., Lee M. L., Gale R. P. Clinical uses of intravenous immunoglobulins. Ann Intern Med. 1990 Feb 15;112(4):278–292. doi: 10.7326/0003-4819-112-4-278. [DOI] [PubMed] [Google Scholar]
  11. Borrebaeck C. A. Strategy for the production of human monoclonal antibodies using in vitro activated B cells. J Immunol Methods. 1989 Oct 24;123(2):157–165. doi: 10.1016/0022-1759(89)90219-6. [DOI] [PubMed] [Google Scholar]
  12. Bost K. L., Hahn B. H., Saag M. S., Shaw G. M., Weigent D. A., Blalock J. E. Individuals infected with HIV possess antibodies against IL-2. Immunology. 1988 Dec;65(4):611–615. [PMC free article] [PubMed] [Google Scholar]
  13. Boyd J. E., James K. Human monoclonal antibodies: their potential, problems, and prospects. Adv Biotechnol Processes. 1989;11:1–43. [PubMed] [Google Scholar]
  14. Boyer V., Broly H., Souche S., Madaule P., Rossier J., Zagury D., Desgranges C. Characterization and large production of human monoclonal antibodies against the HIV-1 envelope. Clin Exp Immunol. 1991 Mar;83(3):452–459. doi: 10.1111/j.1365-2249.1991.tb05660.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Brenneman D. E., Westbrook G. L., Fitzgerald S. P., Ennist D. L., Elkins K. L., Ruff M. R., Pert C. B. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature. 1988 Oct 13;335(6191):639–642. doi: 10.1038/335639a0. [DOI] [PubMed] [Google Scholar]
  16. Broliden P. A., Ljunggren K., Hinkula J., Norrby E., Akerblom L., Wahren B. A monoclonal antibody to human immunodeficiency virus type 1 which mediates cellular cytotoxicity and neutralization. J Virol. 1990 Feb;64(2):936–940. doi: 10.1128/jvi.64.2.936-940.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Bugge T. H., Lindhardt B. O., Hansen L. L., Kusk P., Hulgaard E., Holmbäck K., Klasse P. J., Zeuthen J., Ulrich K. Analysis of a highly immunodominant epitope in the human immunodeficiency virus type 1 transmembrane glycoprotein, gp41, defined by a human monoclonal antibody. J Virol. 1990 Sep;64(9):4123–4129. doi: 10.1128/jvi.64.9.4123-4129.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Byers V. S., Baldwin R. W. Therapeutic strategies with monoclonal antibodies and immunoconjugates. Immunology. 1988 Nov;65(3):329–335. [PMC free article] [PubMed] [Google Scholar]
  19. Böttiger B., Karlsson A., Andreasson P. A., Naucler A., Costa C. M., Biberfeld G. Cross-neutralizing antibodies against HIV-1 (HTLV-IIIB and HTLV-IIIRF) and HIV-2 (SBL-6669 and a new isolate SBL-K135). AIDS Res Hum Retroviruses. 1989 Oct;5(5):525–533. doi: 10.1089/aid.1989.5.525. [DOI] [PubMed] [Google Scholar]
  20. Cauda R., Tumbarello M., Ortona L., Kanda P., Kennedy R. C., Chanh T. C. Inhibition of normal human natural killer cell activity by human immunodeficiency virus synthetic transmembrane peptides. Cell Immunol. 1988 Aug;115(1):57–65. doi: 10.1016/0008-8749(88)90161-x. [DOI] [PubMed] [Google Scholar]
  21. Chams V., Idziorek T., Klatzmann D. Biological properties of anti-CD4 autoantibodies purified from HIV-infected patients. AIDS. 1991 May;5(5):565–569. [PubMed] [Google Scholar]
  22. Chanh T. C., Kennedy R. C., Kanda P. Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic response. Cell Immunol. 1988 Jan;111(1):77–86. doi: 10.1016/0008-8749(88)90052-4. [DOI] [PubMed] [Google Scholar]
  23. Cheng-Mayer C., Homsy J., Evans L. A., Levy J. A. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A. 1988 Apr;85(8):2815–2819. doi: 10.1073/pnas.85.8.2815. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Chiodi F., Mathiesen T., Albert J., Parks E., Norrby E., Wahren B. IgG subclass responses to a transmembrane protein (gp41) peptide in HIV infection. J Immunol. 1989 Jun 1;142(11):3809–3814. [PubMed] [Google Scholar]
  25. Chirmule N., Kalyanaraman V. S., Oyaizu N., Slade H. B., Pahwa S. Inhibition of functional properties of tetanus antigen-specific T-cell clones by envelope glycoprotein GP120 of human immunodeficiency virus. Blood. 1990 Jan 1;75(1):152–159. [PubMed] [Google Scholar]
  26. Chirmule N., Kalyanaraman V. S., Saxinger C., Wong-Staal F., Ghrayeb J., Pahwa S. Localization of B-cell stimulatory activity of HIV-1 to the carboxyl terminus of gp41. AIDS Res Hum Retroviruses. 1990 Mar;6(3):299–305. doi: 10.1089/aid.1990.6.299. [DOI] [PubMed] [Google Scholar]
  27. Cloyd M. W., Holt M. J. Heterogeneity of human immunodeficiency virus cell-associated antigens and demonstration of virus type specificities of human antibody responses. Virology. 1987 Dec;161(2):286–292. doi: 10.1016/0042-6822(87)90120-6. [DOI] [PubMed] [Google Scholar]
  28. Co M. S., Deschamps M., Whitley R. J., Queen C. Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A. 1991 Apr 1;88(7):2869–2873. doi: 10.1073/pnas.88.7.2869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Dalgleish A. G., Chanh T. C., Kennedy R. C., Kanda P., Clapham P. R., Weiss R. A. Neutralization of diverse HIV-1 strains by monoclonal antibodies raised against a gp41 synthetic peptide. Virology. 1988 Jul;165(1):209–215. doi: 10.1016/0042-6822(88)90674-5. [DOI] [PubMed] [Google Scholar]
  30. Dalgleish A. G., Thomson B. J., Chanh T. C., Malkovsky M., Kennedy R. C. Neutralisation of HIV isolates by anti-idiotypic antibodies which mimic the T4 (CD4) epitope: a potential AIDS vaccine. Lancet. 1987 Nov 7;2(8567):1047–1050. doi: 10.1016/s0140-6736(87)91477-2. [DOI] [PubMed] [Google Scholar]
  31. Davis D., Stephens D. M., Willers C., Lachmann P. J. Glycosylation governs the binding of antipeptide antibodies to regions of hypervariable amino acid sequence within recombinant gp120 of human immunodeficiency virus type 1. J Gen Virol. 1990 Dec;71(Pt 12):2889–2898. doi: 10.1099/0022-1317-71-12-2889. [DOI] [PubMed] [Google Scholar]
  32. Desgranges C., Boyer V., Souche S., Sprecher S., Burney A., Gallo R. C., Bernard J., Reveil B., Zagury D. Monoclonal antibodies to HIV in a non-infected, immunised volunteer. Lancet. 1988 Apr 23;1(8591):935–936. doi: 10.1016/s0140-6736(88)91737-0. [DOI] [PubMed] [Google Scholar]
  33. Devash Y., Calvelli T. A., Wood D. G., Reagan K. J., Rubinstein A. Vertical transmission of human immunodeficiency virus is correlated with the absence of high-affinity/avidity maternal antibodies to the gp120 principal neutralizing domain. Proc Natl Acad Sci U S A. 1990 May;87(9):3445–3449. doi: 10.1073/pnas.87.9.3445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Dorfman N. A. The optimal technological approach to the development of human hybridomas. J Biol Response Mod. 1985 Jun;4(3):213–239. [PubMed] [Google Scholar]
  35. Dorsett B., Cronin W., Chuma V., Ioachim H. L. Anti-lymphocyte antibodies in patients with the acquired immune deficiency syndrome. Am J Med. 1985 Apr;78(4):621–626. doi: 10.1016/0002-9343(85)90405-x. [DOI] [PubMed] [Google Scholar]
  36. Dowbenko D., Nakamura G., Fennie C., Shimasaki C., Riddle L., Harris R., Gregory T., Lasky L. Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J Virol. 1988 Dec;62(12):4703–4711. doi: 10.1128/jvi.62.12.4703-4711.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Döpel S. H., Porstmann T., Grunow R., Jungbauer A., Von Baehr R. Application of a human monoclonal antibody in a rapid competitive anti-HIV ELISA. J Immunol Methods. 1989 Jan 17;116(2):229–233. doi: 10.1016/0022-1759(89)90208-1. [DOI] [PubMed] [Google Scholar]
  38. Edelman A. S., Zolla-Pazner S. Response of mononuclear cells from HIV-infected patients to B-cell mitogens: correlation with immunological and clinical features of disease progression. AIDS. 1990 Sep;4(9):859–864. doi: 10.1097/00002030-199009000-00004. [DOI] [PubMed] [Google Scholar]
  39. Evans L. A., Homsy J. M., Morrow W. J., Gaston I., Sooy C. D., Levy J. A. Human monoclonal antibody directed against gag gene products of the human immunodeficiency virus. J Immunol. 1988 Feb 1;140(3):941–943. [PubMed] [Google Scholar]
  40. Ferns R. B., Tedder R. S., Weiss R. A. Characterization of monoclonal antibodies against the human immunodeficiency virus (HIV) gag products and their use in monitoring HIV isolate variation. J Gen Virol. 1987 Jun;68(Pt 6):1543–1551. doi: 10.1099/0022-1317-68-6-1543. [DOI] [PubMed] [Google Scholar]
  41. Folks T. M., Kessler S. W., Orenstein J. M., Justement J. S., Jaffe E. S., Fauci A. S. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science. 1988 Nov 11;242(4880):919–922. doi: 10.1126/science.2460922. [DOI] [PubMed] [Google Scholar]
  42. Foung S., Perkins S., Kafadar K., Gessner P., Zimmermann U. Development of microfusion techniques to generate human hybridomas. J Immunol Methods. 1990 Nov 6;134(1):35–42. doi: 10.1016/0022-1759(90)90109-9. [DOI] [PubMed] [Google Scholar]
  43. Fung M. S., Sun C. R., Liou R. S., Gordon W., Chang N. T., Chang T. W., Sun N. C. Monoclonal anti-idiotypic antibody mimicking the principal neutralization site in HIV-1 GP120 induces HIV-1 neutralizing antibodies in rabbits. J Immunol. 1990 Oct 1;145(7):2199–2206. [PubMed] [Google Scholar]
  44. Gnann J. W., Jr, Nelson J. A., Oldstone M. B. Fine mapping of an immunodominant domain in the transmembrane glycoprotein of human immunodeficiency virus. J Virol. 1987 Aug;61(8):2639–2641. doi: 10.1128/jvi.61.8.2639-2641.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Goedert J. J., Mendez H., Drummond J. E., Robert-Guroff M., Minkoff H. L., Holman S., Stevens R., Rubinstein A., Blattner W. A., Willoughby A. Mother-to-infant transmission of human immunodeficiency virus type 1: association with prematurity or low anti-gp120. Lancet. 1989 Dec 9;2(8676):1351–1354. doi: 10.1016/s0140-6736(89)91965-x. [DOI] [PubMed] [Google Scholar]
  46. Golding H., Robey F. A., Gates F. T., 3rd, Linder W., Beining P. R., Hoffman T., Golding B. Identification of homologous regions in human immunodeficiency virus I gp41 and human MHC class II beta 1 domain. I. Monoclonal antibodies against the gp41-derived peptide and patients' sera react with native HLA class II antigens, suggesting a role for autoimmunity in the pathogenesis of acquired immune deficiency syndrome. J Exp Med. 1988 Mar 1;167(3):914–923. doi: 10.1084/jem.167.3.914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Golding H., Shearer G. M., Hillman K., Lucas P., Manischewitz J., Zajac R. A., Clerici M., Gress R. E., Boswell R. N., Golding B. Common epitope in human immunodeficiency virus (HIV) I-GP41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J Clin Invest. 1989 Apr;83(4):1430–1435. doi: 10.1172/JCI114034. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Gorny M. K., Gianakakos V., Sharpe S., Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci U S A. 1989 Mar;86(5):1624–1628. doi: 10.1073/pnas.86.5.1624. [DOI] [PMC free article] [PubMed] [Google Scholar]
  49. Gorny M. K., Xu J. Y., Gianakakos V., Karwowska S., Williams C., Sheppard H. W., Hanson C. V., Zolla-Pazner S. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci U S A. 1991 Apr 15;88(8):3238–3242. doi: 10.1073/pnas.88.8.3238. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Goudsmit J., Boucher C. A., Meloen R. H., Epstein L. G., Smit L., van der Hoek L., Bakker M. Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition. AIDS. 1988 Jun;2(3):157–164. [PubMed] [Google Scholar]
  51. Grimaldi L. M., Roos R. P., Devare S. G., Robey W. G., Casey J. M., Gurney M. E., Apatoff B. R., Lazzarin D. Restricted heterogeneity of antibody to gp120 and p24 in AIDS. J Immunol. 1988 Jul 1;141(1):114–117. [PubMed] [Google Scholar]
  52. Groopman J. E., Benz P. M., Ferriani R., Mayer K., Allan J. D., Weymouth L. A. Characterization of serum neutralization response to the human immunodeficiency virus (HIV). AIDS Res Hum Retroviruses. 1987 Spring;3(1):71–85. doi: 10.1089/aid.1987.3.71. [DOI] [PubMed] [Google Scholar]
  53. Grunow R., Jahn S., Porstmann T., Kiessig S. S., Steinkellner H., Steindl F., Mattanovich D., Gürtler L., Deinhardt F., Katinger H. The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods. 1988 Feb 10;106(2):257–265. doi: 10.1016/0022-1759(88)90206-2. [DOI] [PubMed] [Google Scholar]
  54. Hansen J. E., Clausen H., Nielsen C., Teglbjaerg L. S., Hansen L. L., Nielsen C. M., Dabelsteen E., Mathiesen L., Hakomori S. I., Nielsen J. O. Inhibition of human immunodeficiency virus (HIV) infection in vitro by anticarbohydrate monoclonal antibodies: peripheral glycosylation of HIV envelope glycoprotein gp120 may be a target for virus neutralization. J Virol. 1990 Jun;64(6):2833–2840. doi: 10.1128/jvi.64.6.2833-2840.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Haseltine W. A. Replication and pathogenesis of the AIDS virus. J Acquir Immune Defic Syndr. 1988;1(3):217–240. [PubMed] [Google Scholar]
  56. Hinkula J., Rosen J., Sundqvist V. A., Stigbrand T., Wahren B. Epitope mapping of the HIV-1 gag region with monoclonal antibodies. Mol Immunol. 1990 May;27(5):395–403. doi: 10.1016/0161-5890(90)90163-t. [DOI] [PubMed] [Google Scholar]
  57. Ho D. D., Kaplan J. C., Rackauskas I. E., Gurney M. E. Second conserved domain of gp120 is important for HIV infectivity and antibody neutralization. Science. 1988 Feb 26;239(4843):1021–1023. doi: 10.1126/science.2830667. [DOI] [PubMed] [Google Scholar]
  58. Ho D. D., McKeating J. A., Li X. L., Moudgil T., Daar E. S., Sun N. C., Robinson J. E. Conformational epitope on gp120 important in CD4 binding and human immunodeficiency virus type 1 neutralization identified by a human monoclonal antibody. J Virol. 1991 Jan;65(1):489–493. doi: 10.1128/jvi.65.1.489-493.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Hofmann B., Lindhardt B. O., Gerstoft J., Petersen C. S., Platz P., Ryder L. P., Odum N., Dickmeiss E., Nielsen P. B., Ullman S. Lymphocyte transformation response to pokeweed mitogen as a predictive marker for development of AIDS and AIDS related symptoms in homosexual men with HIV antibodies. Br Med J (Clin Res Ed) 1987 Aug 1;295(6593):293–296. doi: 10.1136/bmj.295.6593.293. [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. Homsy J., Meyer M., Levy J. A. Serum enhancement of human immunodeficiency virus (HIV) infection correlates with disease in HIV-infected individuals. J Virol. 1990 Apr;64(4):1437–1440. doi: 10.1128/jvi.64.4.1437-1440.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Hunt J. C., Falk L., Webber J. S., Decker R. H., Devare S. G., Dawson G. J. Diagnostic utility of a mouse monoclonal antibody (5-21-3) employed as a competitive probe in an immunoassay to detect antibody to HIV-1 gp41. AIDS Res Hum Retroviruses. 1990 May;6(5):599–606. doi: 10.1089/aid.1990.6.599. [DOI] [PubMed] [Google Scholar]
  62. Jackson G. G., Perkins J. T., Rubenis M., Paul D. A., Knigge M., Despotes J. C., Spencer P. Passive immunoneutralization of human immunodeficiency virus in patients with advanced AIDS. Lancet. 1988 Sep 17;2(8612):647–652. doi: 10.1016/s0140-6736(88)90468-0. [DOI] [PubMed] [Google Scholar]
  63. James K., Bell G. T. Human monoclonal antibody production. Current status and future prospects. J Immunol Methods. 1987 Jun 26;100(1-2):5–40. doi: 10.1016/0022-1759(87)90170-0. [DOI] [PubMed] [Google Scholar]
  64. James K. Human monoclonal antibodies and engineered antibodies in the management of cancer. Semin Cancer Biol. 1990 Jun;1(3):243–253. [PubMed] [Google Scholar]
  65. Javaherian K., Langlois A. J., LaRosa G. J., Profy A. T., Bolognesi D. P., Herlihy W. C., Putney S. D., Matthews T. J. Broadly neutralizing antibodies elicited by the hypervariable neutralizing determinant of HIV-1. Science. 1990 Dec 14;250(4987):1590–1593. doi: 10.1126/science.1703322. [DOI] [PubMed] [Google Scholar]
  66. Jehuda-Cohen T., Slade B. A., Powell J. D., Villinger F., De B., Folks T. M., McClure H. M., Sell K. W., Ahmed-Ansari A. Polyclonal B-cell activation reveals antibodies against human immunodeficiency virus type 1 (HIV-1) in HIV-1-seronegative individuals. Proc Natl Acad Sci U S A. 1990 May;87(10):3972–3976. doi: 10.1073/pnas.87.10.3972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  67. Kaiser P. K., Offermann J. T., Lipton S. A. Neuronal injury due to HIV-1 envelope protein is blocked by anti-gp120 antibodies but not by anti-CD4 antibodies. Neurology. 1990 Nov;40(11):1757–1761. doi: 10.1212/wnl.40.11.1757. [DOI] [PubMed] [Google Scholar]
  68. Karpas A., Hewlett I. K., Hill F., Gray J., Byron N., Gilgen D., Bally V., Oates J. K., Gazzard B., Epstein J. E. Polymerase chain reaction evidence for human immunodeficiency virus 1 neutralization by passive immunization in patients with AIDS and AIDS-related complex. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7613–7617. doi: 10.1073/pnas.87.19.7613. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Kenealy W., Reed D., Cybulski R., Tribe D., Taylor P., Stevens C., Matthews T., Petteway S. Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens. AIDS Res Hum Retroviruses. 1987 Spring;3(1):95–105. doi: 10.1089/aid.1987.3.95. [DOI] [PubMed] [Google Scholar]
  70. Kennedy R. C., Henkel R. D., Pauletti D., Allan J. S., Lee T. H., Essex M., Dreesman G. R. Antiserum to a synthetic peptide recognizes the HTLV-III envelope glycoprotein. Science. 1986 Mar 28;231(4745):1556–1559. doi: 10.1126/science.3006246. [DOI] [PubMed] [Google Scholar]
  71. Khalife J., Guy B., Capron M., Kieny M. P., Ameisen J. C., Montagnier L., Lecocq J. P., Capron A. Isotypic restriction of the antibody response to human immunodeficiency virus. AIDS Res Hum Retroviruses. 1988 Feb;4(1):3–9. doi: 10.1089/aid.1988.4.3. [DOI] [PubMed] [Google Scholar]
  72. Kiprov D. D., Anderson R. E., Morand P. R., Simpson D. M., Chermann J. C., Levy J. A., Ross A. R. Antilymphocyte antibodies and seropositivity for retroviruses in groups at high risk for AIDS. N Engl J Med. 1985 Jun 6;312(23):1517–1517. doi: 10.1056/NEJM198506063122312. [DOI] [PubMed] [Google Scholar]
  73. Klasse J., Blomberg J. Patterns of antibodies to human immunodeficiency virus proteins in different subclasses of IgG. J Infect Dis. 1987 Dec;156(6):1026–1030. doi: 10.1093/infdis/156.6.1026. [DOI] [PubMed] [Google Scholar]
  74. Klasse P. J., Pipkorn R., Blomberg J. Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects. Proc Natl Acad Sci U S A. 1988 Jul;85(14):5225–5229. doi: 10.1073/pnas.85.14.5225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Koup R. A., Sullivan J. L., Levine P. H., Brewster F., Mahr A., Mazzara G., McKenzie S., Panicali D. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol. 1989 Feb;63(2):584–590. doi: 10.1128/jvi.63.2.584-590.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Kozbor D., Lagarde A. E., Roder J. C. Human hybridomas constructed with antigen-specific Epstein-Barr virus-transformed cell lines. Proc Natl Acad Sci U S A. 1982 Nov;79(21):6651–6655. doi: 10.1073/pnas.79.21.6651. [DOI] [PMC free article] [PubMed] [Google Scholar]
  77. Krowka J. F., Singh B., Stites D. P., Maino V. C., Narindray D., Hollander H., Jain S., Chen H., Blackwood L., Steimer K. S. Epitopes of human immunodeficiency virus type 1 (HIV-1) envelope glycoproteins recognized by antibodies in the sera of HIV-1-infected individuals. Clin Immunol Immunopathol. 1991 Apr;59(1):53–64. doi: 10.1016/0090-1229(91)90081-k. [DOI] [PubMed] [Google Scholar]
  78. Krowka J. F., Stites D. P., Jain S., Steimer K. S., George-Nascimento C., Gyenes A., Barr P. J., Hollander H., Moss A. R., Homsy J. M. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest. 1989 Apr;83(4):1198–1203. doi: 10.1172/JCI114001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Köhler G., Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur J Immunol. 1976 Jul;6(7):511–519. doi: 10.1002/eji.1830060713. [DOI] [PubMed] [Google Scholar]
  80. Lake D., Sugano T., Matsumoto Y., Masuho Y., Petersen E. A., Feorino P., Hersh E. M. A hybridoma producing human monoclonal antibody specific for glycoprotein 120 kDa of human immunodeficiency virus (HIV-1. Life Sci. 1989;45(16):iii–x. doi: 10.1016/0024-3205(89)90030-1. [DOI] [PubMed] [Google Scholar]
  81. Lal R. B., Heiba I. M., Dhawan R. R., Smith E. S., Perine P. L. IgG subclass responses to human immunodeficiency virus-1 antigens: lack of IgG2 response to gp41 correlates with clinical manifestation of disease. Clin Immunol Immunopathol. 1991 Feb;58(2):267–277. doi: 10.1016/0090-1229(91)90141-v. [DOI] [PubMed] [Google Scholar]
  82. Lane H. C., Masur H., Edgar L. C., Whalen G., Rook A. H., Fauci A. S. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1983 Aug 25;309(8):453–458. doi: 10.1056/NEJM198308253090803. [DOI] [PubMed] [Google Scholar]
  83. Lange J. M., Paul D. A., Huisman H. G., de Wolf F., van den Berg H., Coutinho R. A., Danner S. A., van der Noordaa J., Goudsmit J. Persistent HIV antigenaemia and decline of HIV core antibodies associated with transition to AIDS. Br Med J (Clin Res Ed) 1986 Dec 6;293(6560):1459–1462. doi: 10.1136/bmj.293.6560.1459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Lasky L. A., Nakamura G., Smith D. H., Fennie C., Shimasaki C., Patzer E., Berman P., Gregory T., Capon D. J. Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor. Cell. 1987 Sep 11;50(6):975–985. doi: 10.1016/0092-8674(87)90524-1. [DOI] [PubMed] [Google Scholar]
  85. Levy J. A. Human immunodeficiency viruses and the pathogenesis of AIDS. JAMA. 1989 May 26;261(20):2997–3006. [PubMed] [Google Scholar]
  86. Liang C. M., Henry S., Liang S. M., Epstein J. S. An anti-p24 monoclonal antibody shows cross-reactivity with multiple HIV-1 proteins. J Immunol Methods. 1990 Aug 28;132(1):57–62. doi: 10.1016/0022-1759(90)90398-f. [DOI] [PubMed] [Google Scholar]
  87. Lifson A. R., Buchbinder S. P., Sheppard H. W., Mawle A. C., Wilber J. C., Stanley M., Hart C. E., Hessol N. A., Holmberg S. D. Long-term human immunodeficiency virus infection in asymptomatic homosexual and bisexual men with normal CD4+ lymphocyte counts: immunologic and virologic characteristics. J Infect Dis. 1991 May;163(5):959–965. doi: 10.1093/infdis/163.5.959. [DOI] [PubMed] [Google Scholar]
  88. Liou R. S., Rosen E. M., Fung M. S., Sun W. N., Sun C., Gordon W., Chang N. T., Chang T. W. A chimeric mouse-human antibody that retains specificity for HIV gp120 and mediates the lysis of HIV-infected cells. J Immunol. 1989 Dec 15;143(12):3967–3975. [PubMed] [Google Scholar]
  89. Ljunggren K., Broliden P. A., Morfeldt-Månson L., Jondal M., Wahren B. IgG subclass response to HIV in relation to antibody-dependent cellular cytotoxicity at different clinical stages. Clin Exp Immunol. 1988 Sep;73(3):343–347. [PMC free article] [PubMed] [Google Scholar]
  90. Ljunggren K., Böttiger B., Biberfeld G., Karlson A., Fenyö E. M., Jondal M. Antibody-dependent cellular cytotoxicity-inducing antibodies against human immunodeficiency virus. Presence at different clinical stages. J Immunol. 1987 Oct 1;139(7):2263–2267. [PubMed] [Google Scholar]
  91. Ljunggren K., Moschese V., Broliden P. A., Giaquinto C., Quinti I., Fenyö E. M., Wahren B., Rossi P., Jondal M. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis. 1990 Feb;161(2):198–202. doi: 10.1093/infdis/161.2.198. [DOI] [PubMed] [Google Scholar]
  92. Lunardi-Iskandar Y., Nugeyre M. T., Georgoulias V., Barré-Sinoussi F., Jasmin C., Chermann J. C. Replication of the human immunodeficiency virus 1 and impaired differentiation of T cells after in vitro infection of bone marrow immature T cells. J Clin Invest. 1989 Feb;83(2):610–615. doi: 10.1172/JCI113924. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Lyerly H. K., Reed D. L., Matthews T. J., Langlois A. J., Ahearne P. A., Petteway S. R., Jr, Weinhold K. J. Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC. AIDS Res Hum Retroviruses. 1987;3(4):409–422. doi: 10.1089/aid.1987.3.409. [DOI] [PubMed] [Google Scholar]
  94. Maeda H., Matsushita S., Eda Y., Kimachi K., Tokiyoshi S., Bendig M. M. Construction of reshaped human antibodies with HIV-neutralizing activity. Hum Antibodies Hybridomas. 1991 Jul;2(3):124–134. [PubMed] [Google Scholar]
  95. Mann D. L., Lasane F., Popovic M., Arthur L. O., Robey W. G., Blattner W. A., Newman M. J. HTLV-III large envelope protein (gp120) suppresses PHA-induced lymphocyte blastogenesis. J Immunol. 1987 Apr 15;138(8):2640–2644. [PubMed] [Google Scholar]
  96. Martínez-Maza O., Crabb E., Mitsuyasu R. T., Fahey J. L., Giorgi J. V. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol. 1987 Jun 1;138(11):3720–3724. [PubMed] [Google Scholar]
  97. Masuda T., Matsushita S., Kuroda M. J., Kannagi M., Takatsuki K., Harada S. Generation of neutralization-resistant HIV-1 in vitro due to amino acid interchanges of third hypervariable env region. J Immunol. 1990 Nov 15;145(10):3240–3246. [PubMed] [Google Scholar]
  98. Mathiesen T., Broliden P. A., Rosen J., Wahren B. Mapping of IgG subclass and T-cell epitopes on HIV proteins by synthetic peptides. Immunology. 1989 Aug;67(4):453–459. [PMC free article] [PubMed] [Google Scholar]
  99. Mathiesen T., Sönnerborg A., von Sydow M., Gaines H., Wahren B. IgG subclass reactivity against human immunodeficiency virus (HIV) and cytomegalovirus in cerebrospinal fluid and serum from HIV-infected patients. J Med Virol. 1988 May;25(1):17–26. doi: 10.1002/jmv.1890250104. [DOI] [PubMed] [Google Scholar]
  100. Matsushita S., Robert-Guroff M., Rusche J., Koito A., Hattori T., Hoshino H., Javaherian K., Takatsuki K., Putney S. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J Virol. 1988 Jun;62(6):2107–2114. doi: 10.1128/jvi.62.6.2107-2114.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. McKeating J. A., Gow J., Goudsmit J., Pearl L. H., Mulder C., Weiss R. A. Characterization of HIV-1 neutralization escape mutants. AIDS. 1989 Dec;3(12):777–784. doi: 10.1097/00002030-198912000-00001. [DOI] [PubMed] [Google Scholar]
  102. McRae B., Lange J. A., Ascher M. S., de Wolf F., Sheppard H. W., Goudsmit J., Allain J. P. Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection. AIDS Res Hum Retroviruses. 1991 Aug;7(8):637–643. doi: 10.1089/aid.1991.7.637. [DOI] [PubMed] [Google Scholar]
  103. Mehta S. U., Rupprecht K. R., Hunt J. C., Kramer D. E., McRae B. J., Allen R. G., Dawson G. J., Devare S. G. Prevalence of antibodies to the core protein P17, a serological marker during HIV-1 infection. AIDS Res Hum Retroviruses. 1990 Apr;6(4):443–454. doi: 10.1089/aid.1990.6.443. [DOI] [PubMed] [Google Scholar]
  104. Miedema F., Petit A. J., Terpstra F. G., Schattenkerk J. K., de Wolf F., Al B. J., Roos M., Lange J. M., Danner S. A., Goudsmit J. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men. HIV affects the immune system before CD4+ T helper cell depletion occurs. J Clin Invest. 1988 Dec;82(6):1908–1914. doi: 10.1172/JCI113809. [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Mizuma H., Litwin S., Zolla-Pazner S. B-cell activation in HIV infection: relationship of spontaneous immunoglobulin secretion to various immunological parameters. Clin Exp Immunol. 1988 Mar;71(3):410–416. [PMC free article] [PubMed] [Google Scholar]
  106. Mizuma H., Zolla-Pazner S., Litwin S., el-Sadr W., Sharpe S., Zehr B., Weiss S., Saxinger W. C., Marmor M. Serum IgD elevation is an early marker of B cell activation during infection with the human immunodeficiency viruses. Clin Exp Immunol. 1987 Apr;68(1):5–14. [PMC free article] [PubMed] [Google Scholar]
  107. Montefiori D. C., Lefkowitz L. B., Jr, Keller R. E., Holmberg V., Sandstrom E., Phair J. P. Absence of a clinical correlation for complement-mediated, infection-enhancing antibodies in plasma or sera from HIV-1-infected individuals. Multicenter AIDS Cohort Study Group. AIDS. 1991 May;5(5):513–517. doi: 10.1097/00002030-199105000-00006. [DOI] [PubMed] [Google Scholar]
  108. Moore G. P. Genetically engineered antibodies. Clin Chem. 1989 Sep;35(9):1849–1853. [PubMed] [Google Scholar]
  109. Nair M. P., Pottathil R., Heimer E. P., Schwartz S. A. Immunoregulatory activities of human immunodeficiency virus (HIV) proteins: effect of HIV recombinant and synthetic peptides on immunoglobulin synthesis and proliferative responses by normal lymphocytes. Proc Natl Acad Sci U S A. 1988 Sep;85(17):6498–6502. doi: 10.1073/pnas.85.17.6498. [DOI] [PMC free article] [PubMed] [Google Scholar]
  110. Neurath A. R., Strick N., Taylor P., Rubinstein P., Stevens C. E. Search for epitope-specific antibody responses to the human immunodeficiency virus (HIV-1) envelope glycoproteins signifying resistance to disease development. AIDS Res Hum Retroviruses. 1990 Oct;6(10):1183–1192. doi: 10.1089/aid.1990.6.1183. [DOI] [PubMed] [Google Scholar]
  111. Nicholson J. K., McDougal J. S., Spira T. J., Cross G. D., Jones B. M., Reinherz E. L. Immunoregulatory subsets of the T helper and T suppressor cell populations in homosexual men with chronic unexplained lymphadenopathy. J Clin Invest. 1984 Jan;73(1):191–201. doi: 10.1172/JCI111190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Närvänen A., Korkolainen M., Kontio S., Suni J., Turtianen S., Partanen P., Soos J., Vaheri A., Huhtala M. L. Highly immunoreactive antigenic site in a hydrophobic domain of HIV-1 gp41 which remains undetectable with conventional immunochemical methods. AIDS. 1988 Apr;2(2):119–123. doi: 10.1097/00002030-198804000-00008. [DOI] [PubMed] [Google Scholar]
  113. Ohlin M., Broliden P. A., Danielsson L., Wahren B., Rosen J., Jondal M., Borrebaeck C. A. Human monoclonal antibodies against a recombinant HIV envelope antigen produced by primary in vitro immunization. Characterization and epitope mapping. Immunology. 1989 Nov;68(3):325–331. [PMC free article] [PubMed] [Google Scholar]
  114. Ozturk G. E., Kohler P. F., Horsburgh C. R., Jr, Kirkpatrick C. H. The significance of antilymphocyte antibodies in patients with acquired immune deficiency syndrome (AIDS) and their sexual partners. J Clin Immunol. 1987 Mar;7(2):130–139. doi: 10.1007/BF00916007. [DOI] [PubMed] [Google Scholar]
  115. Pahwa S., Chirmule N., Leombruno C., Lim W., Harper R., Bhalla R., Pahwa R., Nelson R. P., Good R. A. In vitro synthesis of human immunodeficiency virus-specific antibodies in peripheral blood lymphocytes of infants. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7532–7536. doi: 10.1073/pnas.86.19.7532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Pahwa S., Pahwa R., Good R. A., Gallo R. C., Saxinger C. Stimulatory and inhibitory influences of human immunodeficiency virus on normal B lymphocytes. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9124–9128. doi: 10.1073/pnas.83.23.9124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Pahwa S., Pahwa R., Saxinger C., Gallo R. C., Good R. A. Influence of the human T-lymphotropic virus/lymphadenopathy-associated virus on functions of human lymphocytes: evidence for immunosuppressive effects and polyclonal B-cell activation by banded viral preparations. Proc Natl Acad Sci U S A. 1985 Dec;82(23):8198–8202. doi: 10.1073/pnas.82.23.8198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  118. Pan L. Z., Cheng-Mayer C., Levy J. A. Patterns of antibody response in individuals infected with the human immunodeficiency virus. J Infect Dis. 1987 Apr;155(4):626–632. doi: 10.1093/infdis/155.4.626. [DOI] [PubMed] [Google Scholar]
  119. Papsidero L. D., Sheu M., Ruscetti F. W. Human immunodeficiency virus type 1-neutralizing monoclonal antibodies which react with p17 core protein: characterization and epitope mapping. J Virol. 1989 Jan;63(1):267–272. doi: 10.1128/jvi.63.1.267-272.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Persson M. A., Caothien R. H., Burton D. R. Generation of diverse high-affinity human monoclonal antibodies by repertoire cloning. Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2432–2436. doi: 10.1073/pnas.88.6.2432. [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Pinching A. J. Antibody responses in HIV infection. Clin Exp Immunol. 1991 May;84(2):181–184. [PMC free article] [PubMed] [Google Scholar]
  122. Pincus S. H., Cole R. L., Hersh E. M., Lake D., Masuho Y., Durda P. J., McClure J. In vitro efficacy of anti-HIV immunotoxins targeted by various antibodies to the envelope protein. J Immunol. 1991 Jun 15;146(12):4315–4324. [PubMed] [Google Scholar]
  123. Pollock B. J., McKenzie A. S., Kemp B. E., McPhee D. A., D'Apice A. J. Human monoclonal antibodies to HIV-1: cross-reactions with gag and env products. Clin Exp Immunol. 1989 Dec;78(3):323–328. [PMC free article] [PubMed] [Google Scholar]
  124. Posner M. R., Hideshima T., Cannon T., Mukherjee M., Mayer K. H., Byrn R. A. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol. 1991 Jun 15;146(12):4325–4332. [PubMed] [Google Scholar]
  125. Prigent S., Goossens D., Clerget-Raslain B., Bahraoui E., Roussel M., Tsikas G., Laurent A., Montagnier L., Salmon C., Gluckman J. C. Production and characterization of human monoclonal antibodies against core protein p25 and transmembrane glycoprotein gp41 of HIV-1. AIDS. 1990 Jan;4(1):11–19. doi: 10.1097/00002030-199001000-00002. [DOI] [PubMed] [Google Scholar]
  126. Prince A. M., Pascual D., Kosolapov L. B., Kurokawa D., Baker L., Rubinstein P. Prevalence, clinical significance, and strain specificity of neutralizing antibody to the human immunodeficiency virus. J Infect Dis. 1987 Aug;156(2):268–272. doi: 10.1093/infdis/156.2.268. [DOI] [PubMed] [Google Scholar]
  127. Ranki A., Weiss S. H., Valle S. L., Antonen J., Krohn K. J. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins. Clin Exp Immunol. 1987 Aug;69(2):231–239. [PMC free article] [PubMed] [Google Scholar]
  128. Reiher W. E., 3rd, Blalock J. E., Brunck T. K. Sequence homology between acquired immunodeficiency syndrome virus envelope protein and interleukin 2. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9188–9192. doi: 10.1073/pnas.83.23.9188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  129. Riechmann L., Clark M., Waldmann H., Winter G. Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323–327. doi: 10.1038/332323a0. [DOI] [PubMed] [Google Scholar]
  130. Robert-Guroff M., Oleske J. M., Connor E. M., Epstein L. G., Minnefor A. B., Gallo R. C. Relationship between HTLV-III neutralizing antibody and clinical status of pediatric acquired immunodeficiency syndrome (AIDS) and AIDS-related complex cases. Pediatr Res. 1987 Jun;21(6):547–550. doi: 10.1203/00006450-198706000-00008. [DOI] [PubMed] [Google Scholar]
  131. Robert-Guroff M., Reitz M. S., Jr, Robey W. G., Gallo R. C. In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol. 1986 Nov 15;137(10):3306–3309. [PubMed] [Google Scholar]
  132. Robinson J. E., Holton D., Pacheco-Morell S., Liu J., McMurdo H. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res Hum Retroviruses. 1990 May;6(5):567–579. doi: 10.1089/aid.1990.6.567. [DOI] [PubMed] [Google Scholar]
  133. Robinson W. E., Jr, Gorny M. K., Xu J. Y., Mitchell W. M., Zolla-Pazner S. Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro. J Virol. 1991 Aug;65(8):4169–4176. doi: 10.1128/jvi.65.8.4169-4176.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Robinson W. E., Jr, Kawamura T., Gorny M. K., Lake D., Xu J. Y., Matsumoto Y., Sugano T., Masuho Y., Mitchell W. M., Hersh E. Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro. Proc Natl Acad Sci U S A. 1990 Apr;87(8):3185–3189. doi: 10.1073/pnas.87.8.3185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Robinson W. E., Jr, Kawamura T., Lake D., Masuho Y., Mitchell W. M., Hersh E. M. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol. 1990 Nov;64(11):5301–5305. doi: 10.1128/jvi.64.11.5301-5305.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  136. Rossi P., Moschese V., Broliden P. A., Fundaró C., Quinti I., Plebani A., Giaquinto C., Tovo P. A., Ljunggren K., Rosen J. Presence of maternal antibodies to human immunodeficiency virus 1 envelope glycoprotein gp120 epitopes correlates with the uninfected status of children born to seropositive mothers. Proc Natl Acad Sci U S A. 1989 Oct;86(20):8055–8058. doi: 10.1073/pnas.86.20.8055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  137. Sano K., Lee M. H., Morales F., Nishanian P., Fahey J., Detels R., Imagawa D. T. Antibody that inhibits human immunodeficiency virus reverse transcriptase and association with inability to isolate virus. J Clin Microbiol. 1987 Dec;25(12):2415–2417. doi: 10.1128/jcm.25.12.2415-2417.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Schnittman S. M., Lane H. C., Higgins S. E., Folks T., Fauci A. S. Direct polyclonal activation of human B lymphocytes by the acquired immune deficiency syndrome virus. Science. 1986 Sep 5;233(4768):1084–1086. doi: 10.1126/science.3016902. [DOI] [PubMed] [Google Scholar]
  139. Scott C. F., Jr, Silver S., Profy A. T., Putney S. D., Langlois A., Weinhold K., Robinson J. E. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8597–8601. doi: 10.1073/pnas.87.21.8597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Shalaby M. R., Krowka J. F., Gregory T. J., Hirabayashi S. E., McCabe S. M., Kaufman D. S., Stites D. P., Ammann A. J. The effects of human immunodeficiency virus recombinant envelope glycoprotein on immune cell functions in vitro. Cell Immunol. 1987 Nov;110(1):140–148. doi: 10.1016/0008-8749(87)90108-0. [DOI] [PubMed] [Google Scholar]
  141. Shepp D. H., Chakrabarti S., Moss B., Quinnan G. V., Jr Antibody-dependent cellular cytotoxicity specific for the envelope antigens of human immunodeficiency virus. J Infect Dis. 1988 Jun;157(6):1260–1264. doi: 10.1093/infdis/157.6.1260. [DOI] [PubMed] [Google Scholar]
  142. Silvestris F., Edwards B. S., Sadeghi O. M., Frassanito M. A., Williams R. C., Jr, Dammacco F. Isotype, distribution and target analysis of lymphocyte reactive antibodies in patients with human immunodeficiency virus infection. Clin Immunol Immunopathol. 1989 Nov;53(2 Pt 1):329–340. doi: 10.1016/0090-1229(89)90061-5. [DOI] [PubMed] [Google Scholar]
  143. Steinberg H. N., Crumpacker C. S., Chatis P. A. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol. 1991 Apr;65(4):1765–1769. doi: 10.1128/jvi.65.4.1765-1769.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  144. Stricker R. B., McHugh T. M., Moody D. J., Morrow W. J., Stites D. P., Shuman M. A., Levy J. A. An AIDS-related cytotoxic autoantibody reacts with a specific antigen on stimulated CD4+ T cells. 1987 Jun 25-Jul 1Nature. 327(6124):710–713. doi: 10.1038/327710a0. [DOI] [PubMed] [Google Scholar]
  145. Sugano T., Masuho Y., Matsumoto Y., Lake D., Gschwind C., Petersen E. A., Hersh E. M. Human monoclonal antibody against glycoproteins of human immunodeficiency virus. Biochem Biophys Res Commun. 1988 Sep 30;155(3):1105–1112. doi: 10.1016/s0006-291x(88)81254-3. [DOI] [PubMed] [Google Scholar]
  146. Sundqvist V. A., Linde A., Kurth R., Werner A., Helm E. B., Popovic M., Gallo R. C., Wahren B. Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome. J Infect Dis. 1986 May;153(5):970–973. doi: 10.1093/infdis/153.5.970. [DOI] [PubMed] [Google Scholar]
  147. Takeda A., Tuazon C. U., Ennis F. A. Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science. 1988 Oct 28;242(4878):580–583. doi: 10.1126/science.2972065. [DOI] [PubMed] [Google Scholar]
  148. Teeuwsen V. J., Lange J. M., Keet R., Schattenkerk J. K., Debouck C., van den Akker R., Goudsmit J., Osterhaus A. D. Low number of functionally active B lymphocytes in the peripheral blood of HIV-1-seropositive individuals with low p24-specific serum antibody titers. AIDS. 1991 Aug;5(8):971–979. doi: 10.1097/00002030-199108000-00008. [DOI] [PubMed] [Google Scholar]
  149. Teeuwsen V. J., Logtenberg T., Siebelink K. H., Lange J. M., Goudsmit J., Uytdehaag F. G., Osterhaus A. D. Analysis of the antigen- and mitogen-induced differentiation of B lymphocytes from asymptomatic human immunodeficiency virus-seropositive male homosexuals. Discrepancy between T cell-dependent and T cell-independent activation. J Immunol. 1987 Nov 1;139(9):2929–2935. [PubMed] [Google Scholar]
  150. Teeuwsen V. J., Schalken J. J., van der Groen G., van de Akker R., Goudsmit J., Osterhaus A. D. An inhibition enzyme immunoassay using a human monoclonal antibody (K14) reactive with gp41 of HIV-1 for the serology of HIV-1 infections. AIDS. 1991 Jul;5(7):893–896. doi: 10.1097/00002030-199107000-00017. [DOI] [PubMed] [Google Scholar]
  151. Teeuwsen V. J., Siebelink K. H., Crush-Stanton S., Swerdlow B., Schalken J. J., Goudsmit J., van de Akker R., Stukart M. J., Uytdehaag F. G., Osterhaus A. D. Production and characterization of a human monoclonal antibody, reactive with a conserved epitope on gp41 of human immunodeficiency virus type I. AIDS Res Hum Retroviruses. 1990 Mar;6(3):381–392. doi: 10.1089/aid.1990.6.381. [DOI] [PubMed] [Google Scholar]
  152. Tenner-Rácz K., Rácz P., Dietrich M., Kern P., Janossy G., Veronese-Dimarzo F., Klatzmann D., Gluckman J. C., Popovic M. Monoclonal antibodies to human immunodeficiency virus: their relation to the patterns of lymph node changes in persistent generalized lymphadenopathy and AIDS. AIDS. 1987 Jul;1(2):95–104. [PubMed] [Google Scholar]
  153. Thomas E. K., Weber J. N., McClure J., Clapham P. R., Singhal M. C., Shriver M. K., Weiss R. A. Neutralizing monoclonal antibodies to the AIDS virus. AIDS. 1988 Feb;2(1):25–29. doi: 10.1097/00002030-198802000-00004. [DOI] [PubMed] [Google Scholar]
  154. Till M. A., Zolla-Pazner S., Gorny M. K., Patton J. S., Uhr J. W., Vitetta E. S. Human immunodeficiency virus-infected T cells and monocytes are killed by monoclonal human anti-gp41 antibodies coupled to ricin A chain. Proc Natl Acad Sci U S A. 1989 Mar;86(6):1987–1991. doi: 10.1073/pnas.86.6.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Tilley S. A., Honnen W. J., Racho M. E., Hilgartner M., Pinter A. A human monoclonal antibody against the CD4-binding site of HIV1 gp120 exhibits potent, broadly neutralizing activity. Res Virol. 1991 Jul-Aug;142(4):247–259. doi: 10.1016/0923-2516(91)90010-z. [DOI] [PubMed] [Google Scholar]
  156. Tomiyama T., Lake D., Masuho Y., Hersh E. M. Recognition of human immunodeficiency virus glycoproteins by natural anti-carbohydrate antibodies in human serum. Biochem Biophys Res Commun. 1991 May 31;177(1):279–285. doi: 10.1016/0006-291x(91)91979-m. [DOI] [PubMed] [Google Scholar]
  157. Tosato G., Blaese R. M., Yarchoan R. Relationship between immunoglobulin production and immortalization by Epstein Barr virus. J Immunol. 1985 Aug;135(2):959–964. [PubMed] [Google Scholar]
  158. Tyler D. S., Stanley S. D., Zolla-Pazner S., Gorny M. K., Shadduck P. P., Langlois A. J., Matthews T. J., Bolognesi D. P., Palker T. J., Weinhold K. J. Identification of sites within gp41 that serve as targets for antibody-dependent cellular cytotoxicity by using human monoclonal antibodies. J Immunol. 1990 Nov 15;145(10):3276–3282. [PubMed] [Google Scholar]
  159. Tóth F. D., Szabó B., Ujhelyi E., Pálóczi K., Horváth A., Füst G., Kiss J., Bánhegyi D., Hollán S. R. Neutralizing and complement-dependent enhancing antibodies in different stages of HIV infection. AIDS. 1991 Mar;5(3):263–268. doi: 10.1097/00002030-199103000-00003. [DOI] [PubMed] [Google Scholar]
  160. Van Kroonenburgh M. J., Pauwels E. K. Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. Nucl Med Commun. 1988 Nov;9(11):919–930. doi: 10.1097/00006231-198811000-00009. [DOI] [PubMed] [Google Scholar]
  161. Viscidi R. P., Mayur K., Lederman H. M., Frankel A. D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science. 1989 Dec 22;246(4937):1606–1608. doi: 10.1126/science.2556795. [DOI] [PubMed] [Google Scholar]
  162. Wasserman R. L., Budens R. D., Thaxton E. S. In vitro stimulation prior to fusion generates antigen-binding human-human hybridomas. J Immunol Methods. 1986 Nov 6;93(2):275–283. doi: 10.1016/0022-1759(86)90200-0. [DOI] [PubMed] [Google Scholar]
  163. Weinhold K. J., Lyerly H. K., Matthews T. J., Tyler D. S., Ahearne P. M., Stine K. C., Langlois A. J., Durack D. T., Bolognesi D. P. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals. Lancet. 1988 Apr 23;1(8591):902–905. doi: 10.1016/s0140-6736(88)91713-8. [DOI] [PubMed] [Google Scholar]
  164. Weiss R. A., Clapham P. R., Weber J. N., Dalgleish A. G., Lasky L. A., Berman P. W. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature. 1986 Dec 11;324(6097):572–575. doi: 10.1038/324572a0. [DOI] [PubMed] [Google Scholar]
  165. Weiss R. A., Clapham P. R., Weber J. N., Whitby D., Tedder R. S., O'Connor T., Chamaret S., Montagnier L. HIV-2 antisera cross-neutralize HIV-1. AIDS. 1988 Apr;2(2):95–100. doi: 10.1097/00002030-198804000-00004. [DOI] [PubMed] [Google Scholar]
  166. Wendler I., Bienzle U., Hunsmann G. Neutralizing antibodies and the course of HIV-induced disease. AIDS Res Hum Retroviruses. 1987 Summer;3(2):157–163. doi: 10.1089/aid.1987.3.157. [DOI] [PubMed] [Google Scholar]
  167. Xu J. Y., Gorny M. K., Palker T., Karwowska S., Zolla-Pazner S. Epitope mapping of two immunodominant domains of gp41, the transmembrane protein of human immunodeficiency virus type 1, using ten human monoclonal antibodies. J Virol. 1991 Sep;65(9):4832–4838. doi: 10.1128/jvi.65.9.4832-4838.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  168. Yarchoan R., Redfield R. R., Broder S. Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. Contribution of antibody-producing B cells, of Epstein-Barr virus-infected B cells, and of immunoglobulin production induced by human T cell lymphotropic virus, type III/lymphadenopathy-associated virus. J Clin Invest. 1986 Aug;78(2):439–447. doi: 10.1172/JCI112595. [DOI] [PMC free article] [PubMed] [Google Scholar]
  169. Zagury D., Bernard J., Cheynier R., Desportes I., Leonard R., Fouchard M., Reveil B., Ittele D., Lurhuma Z., Mbayo K. A group specific anamnestic immune reaction against HIV-1 induced by a candidate vaccine against AIDS. Nature. 1988 Apr 21;332(6166):728–731. doi: 10.1038/332728a0. [DOI] [PubMed] [Google Scholar]
  170. Zolla-Pazner S., Pinter A., Mizuma H. Potential use of serotherapy in the prevention and treatment of infection with the human immunodeficiency virus. J Virol Methods. 1987 Aug;17(1-2):45–53. doi: 10.1016/0166-0934(87)90067-x. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES